{
  "id": "resp_042d5668ed0788e200693c804b7ae88197855327736b05df36",
  "object": "response",
  "created_at": 1765572683,
  "status": "completed",
  "background": false,
  "billing": {
    "payer": "developer"
  },
  "error": null,
  "incomplete_details": null,
  "instructions": null,
  "max_output_tokens": null,
  "max_tool_calls": null,
  "model": "gpt-5.2-2025-12-11",
  "output": [
    {
      "id": "rs_042d5668ed0788e200693c804c9e588197a1e138b30397e0b3",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_042d5668ed0788e200693c804eeaec8197b9fffe17d58d217e",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "JS207 CDK12"
      }
    },
    {
      "id": "rs_042d5668ed0788e200693c8050d9988197aa2e180f474637a8",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_042d5668ed0788e200693c8053e3b081979e8c703677a1e7a1",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://clinicaltrials.gov/study/NCT07045311"
      }
    },
    {
      "id": "rs_042d5668ed0788e200693c805542608197bd7074897037e8a5",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_042d5668ed0788e200693c8056377c81979e2819cf1a8039a3",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "Sponsor",
        "url": "https://clinicaltrials.gov/study/NCT07045311"
      }
    },
    {
      "id": "rs_042d5668ed0788e200693c8057992c81978142eba602ba69a6",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_042d5668ed0788e200693c805cb4708197be00432939bf6a26",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://ichgcp.net/clinical-trials-registry/NCT07045311"
      }
    },
    {
      "id": "rs_042d5668ed0788e200693c805d75a88197b8d93188fe92846d",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_042d5668ed0788e200693c806ac4f88197a71ea9c1a9bcb447",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "Sponsor",
        "url": "https://ichgcp.net/clinical-trials-registry/NCT07045311"
      }
    },
    {
      "id": "rs_042d5668ed0788e200693c806c6bc08197a8fa6e1871fb6ea1",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_042d5668ed0788e200693c807535648197bce8966fda559c58",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.biospace.com/press-releases/junshi-biosciences-announces-fdas-approval-of-ind-application-for-phase-2-3-clinical-study-of-js207-for-the-neoadjuvant-treatment-of-nsclc-patients"
      }
    },
    {
      "id": "rs_042d5668ed0788e200693c80768ca8819783dfb5e7e6daad43",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_042d5668ed0788e200693c807796488197a040b5b7a0461318",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://pubmed.ncbi.nlm.nih.gov/40607397/"
      }
    },
    {
      "id": "rs_042d5668ed0788e200693c8078658881978ec635ad55d067cf",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "msg_042d5668ed0788e200693c80a3e8248197821900027bb53c3d",
      "type": "message",
      "status": "completed",
      "content": [
        {
          "type": "output_text",
          "annotations": [],
          "logprobs": [],
          "text": "{\n  \"validated\": true,\n  \"assets\": [\n    {\n      \"drug_name_code\": \"JS207\",\n      \"sponsor\": \"Shanghai Junshi Bioscience Co., Ltd.\",\n      \"target\": \"PD-1 and VEGFA\",\n      \"modality\": \"Recombinant humanized bispecific antibody (anti-PD-1/anti-VEGF)\",\n      \"indication\": \"Recurrent or metastatic triple-negative breast cancer (TNBC)\",\n      \"development_stage\": \"Phase 2 (Recruiting)\",\n      \"geography\": \"China\",\n      \"sources\": [\n        \"https://ichgcp.net/clinical-trials-registry/NCT07045311\",\n        \"https://clinicaltrials.gov/study/NCT07045311\",\n        \"https://www.biospace.com/press-releases/junshi-biosciences-announces-fdas-approval-of-ind-application-for-phase-2-3-clinical-study-of-js207-for-the-neoadjuvant-treatment-of-nsclc-patients\",\n        \"https://pubmed.ncbi.nlm.nih.gov/40607397/\"\n      ]\n    }\n  ],\n  \"rejected_reason\": null\n}"
        }
      ],
      "role": "assistant"
    }
  ],
  "parallel_tool_calls": true,
  "previous_response_id": null,
  "prompt_cache_key": null,
  "prompt_cache_retention": null,
  "reasoning": {
    "effort": "xhigh",
    "summary": null
  },
  "safety_identifier": null,
  "service_tier": "default",
  "store": true,
  "temperature": 1.0,
  "text": {
    "format": {
      "type": "text"
    },
    "verbosity": "medium"
  },
  "tool_choice": "auto",
  "tools": [
    {
      "type": "web_search",
      "filters": null,
      "search_context_size": "medium",
      "user_location": {
        "type": "approximate",
        "city": null,
        "country": "US",
        "region": null,
        "timezone": null
      }
    }
  ],
  "top_logprobs": 0,
  "top_p": 0.98,
  "truncation": "disabled",
  "usage": {
    "input_tokens": 27867,
    "input_tokens_details": {
      "cached_tokens": 4736
    },
    "output_tokens": 5426,
    "output_tokens_details": {
      "reasoning_tokens": 5172
    },
    "total_tokens": 33293
  },
  "user": null,
  "metadata": {}
}